Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)

Trial Profile

Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abicipar pegol (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MAPLE
  • Sponsors Allergan
  • Most Recent Events

    • 02 Apr 2019 According to an Allergan Media Release, results of this study enabled to assess improvements to the manufacturing process for abicipar. Additional data from the MAPLE study will be presented at a scientific conference later in 2019.
    • 02 Apr 2019 Topline safety results published in an Allergan Media Release
    • 02 Apr 2019 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top